Autolus Therapeutics (NASDAQ:AUTL) Announces Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) posted its quarterly earnings data on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12, Zacks reports. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.98 million.

Autolus Therapeutics Stock Performance

AUTL stock opened at $1.68 on Friday. Autolus Therapeutics has a fifty-two week low of $1.66 and a fifty-two week high of $6.60. The company’s 50 day moving average price is $2.03 and its 200 day moving average price is $2.93. The firm has a market capitalization of $445.71 million, a price-to-earnings ratio of -1.38 and a beta of 2.07.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.